Every 10-Q that Harmony Biosciences Holdings, Inc. (HRMY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow HRMY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HRMY filings page.
Harmony Biosciences Holdings, Inc. reported higher profitability for Q2 2026, with net product revenue of 261,280 (in thousands) versus 200,489 a year earlier and net income of 75,431 versus 39,776. Diluted earnings per share were 1.28 compared with 0.68.
For the first six months of 2026, net product revenue reached 476,667 and net income was 107,919. Operating cash flow was 120,192, and cash, cash equivalents and investments totaled 962,459 as of June 30, 2026; the company states this should meet operational needs for at least twelve months. Long-term debt principal outstanding was 155,000.
WAKIX remains the only commercial product, while the pipeline includes a Phase 3 Prader–Willi syndrome study and new pitolisant formulations. An NDA for Pitolisant GR has been accepted with a PDUFA date of April 1, 2027. The company has settled several generic WAKIX ANDA actions with licensed entry generally around 2030, while other patent and antitrust-related proceedings continue.
Harmony Biosciences Holdings, Inc. reported continued profitability for the quarter ended March 31, 2026. Net product revenue rose to $215.4 million from $184.7 million a year earlier, driven by growth of WAKIX in narcolepsy.
Higher research and development spending, including $32.0 million of acquired in-process R&D and new license upfronts, reduced net income to $32.5 million from $45.6 million. Diluted earnings per share were $0.55 versus $0.78 in the prior-year period.
Harmony ended the quarter with strong liquidity, holding $589.4 million in cash and cash equivalents and $281.1 million in short- and long-term investments, and a $160.0 million term loan outstanding. Management believes current cash, investments and cash flows will fund operations and planned investing activities for at least the next twelve months.
Harmony Biosciences (HRMY) reported strong Q3 2025 results. Net product revenue reached $239,455, generating gross profit of $179,805 and operating income of $65,487. Net income was $50,865, with diluted EPS of $0.87 on 58,717,910 weighted-average diluted shares.
R&D expense rose to $54,962 as the company advanced programs, while sales and marketing and G&A were $29,549 and $29,807, respectively. Cash and cash equivalents were $646,999, and total cash, cash equivalents and investments were $778,412 as of September 30, 2025. Long-term debt principal stood at $170,000 with a 2028 maturity schedule. The company triggered a $15,000 CVR payment tied to a Zynerba milestone, payable in Q4 2025. As of October 31, 2025, 57,596,358 common shares were outstanding. The ANDA settlements allow licensed generic entry beginning January 2030, or earlier under certain circumstances.